Osteogenesis imperfecta therapy reshapes around anti-sclerostin programs
Setrusumab pivotal data, bisphosphonate maturity, and emerging gene therapy programs are reshaping osteogenesis imperfecta management.
Osteogenesis imperfecta has been a bisphosphonate, supportive-care, and orthopaedic-management category. Setrusumab (anti-sclerostin antibody) is in pivotal trials with the proposition of disease-modifying bone-strengthening therapy specifically for OI, follow-on anti-sclerostin programs and emerging gene therapy programs targeting the underlying collagen-pathway defect are reading out. The category is structurally evolving for the first time in decades.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.